On the public citation graph
mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection
0 signed · 92 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/1521-4141(200001)30:1<1::aid-immu1>3.0.co;2-#openalex-snapshot
In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies
inferredcites →https://doi.org/10.1002/jgm.2605openalex-snapshot
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect
inferredcites →https://doi.org/10.1007/s00508-021-01922-yopenalex-snapshot
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2
inferredcites →https://doi.org/10.1016/j.cell.2020.02.052openalex-snapshot
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
inferredcites →https://doi.org/10.1016/j.cell.2020.05.015openalex-snapshot
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
inferredcites →https://doi.org/10.1016/j.cell.2020.08.017openalex-snapshot
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
inferredcites →https://doi.org/10.1016/j.immuni.2020.04.023openalex-snapshot
Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals
inferredcites →https://doi.org/10.1016/j.vaccine.2020.10.064openalex-snapshot
NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
inferredcites →https://doi.org/10.1016/j.vaccine.2020.12.070openalex-snapshot
Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial
inferredcites →https://doi.org/10.1016/s0140-6736(17)31665-3openalex-snapshot
Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial
inferredcites →https://doi.org/10.1016/s0140-6736(20)32661-1openalex-snapshot
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
inferredcites →https://doi.org/10.1038/nbt.2436openalex-snapshot
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection
inferredcites →https://doi.org/10.1038/s41401-020-0485-4openalex-snapshot
Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19
inferredcites →https://doi.org/10.1038/s41467-021-21389-9openalex-snapshot
Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19
inferredcites →https://doi.org/10.1038/s41541-017-0032-6openalex-snapshot
Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines
inferredcites →https://doi.org/10.1038/s41541-021-00311-wopenalex-snapshot
mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
inferredcites →https://doi.org/10.1038/s41564-020-00789-5openalex-snapshot
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
inferredcites →https://doi.org/10.1038/s41564-020-0688-yopenalex-snapshot
Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
inferredcites →https://doi.org/10.1038/s41586-020-03041-6openalex-snapshot
Correlates of protection against SARS-CoV-2 in rhesus macaques
inferredcites →https://doi.org/10.1038/s41586-020-2012-7openalex-snapshot
A pneumonia outbreak associated with a new coronavirus of probable bat origin
inferredcites →https://doi.org/10.1038/s41586-020-2381-yopenalex-snapshot
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
inferredcites →https://doi.org/10.1038/s41586-020-2599-8openalex-snapshot
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
inferredcites →https://doi.org/10.1038/s41586-020-2607-zopenalex-snapshot
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
inferredcites →https://doi.org/10.1038/s41586-020-2639-4openalex-snapshot
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
inferredcites →https://doi.org/10.1038/s41598-018-34171-7openalex-snapshot
Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis
inferredcites →https://doi.org/10.1038/s41598-018-36918-8openalex-snapshot
Publisher Correction: Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis
inferredcites →https://doi.org/10.1056/nejmoa2024671openalex-snapshot
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
inferredcites →https://doi.org/10.1056/nejmoa2028436openalex-snapshot
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
inferredcites →https://doi.org/10.1056/nejmoa2034577openalex-snapshot
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
inferredcites →https://doi.org/10.1073/pnas.1707304114openalex-snapshot
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
inferredcites →https://doi.org/10.1097/cji.0b013e3181f7dbe8openalex-snapshot
Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity
inferredcites →https://doi.org/10.1101/2020.05.13.093195openalex-snapshot
ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques
inferredcites →https://doi.org/10.1101/2020.09.08.280818openalex-snapshot
A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates
inferredcites →https://doi.org/10.1101/2020.10.14.337535openalex-snapshot
Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and non-human primates
inferredcites →https://doi.org/10.1126/science.abb8923openalex-snapshot
Rapid COVID-19 vaccine development
inferredcites →https://doi.org/10.1128/jvi.66.2.956-965.1992openalex-snapshot
Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages
inferredcites →https://doi.org/10.1186/s40425-015-0068-yopenalex-snapshot
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
inferredcites →https://doi.org/10.1371/journal.pntd.0004746openalex-snapshot
An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs
inferredcites →https://doi.org/10.1371/journal.pntd.0006108openalex-snapshot
A thermostable messenger RNA based vaccine against rabies
inferredcites →https://doi.org/10.3389/fmicb.2018.02991openalex-snapshot
Viral-Induced Enhanced Disease Illness
inferredcites →https://doi.org/10.3389/fmicb.2019.01781openalex-snapshot
Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus
inferredcites →https://doi.org/10.3390/v11010059openalex-snapshot
From SARS to MERS, Thrusting Coronaviruses into the Spotlight
inferredcites →https://doi.org/10.5694/mja2.50569openalex-snapshot
Isolation and rapid sharing of the 2019 novel coronavirus ( SARS ‐CoV‐2) from the first patient diagnosed with COVID ‐19 in Australia
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1002/rmv.2313openalex-snapshot
Covid‐19 vaccines and variants of concern: A review
inferred← citeshttps://doi.org/10.1007/978-3-031-08415-7_2openalex-snapshot
Messenger RNA for Prophylaxis
inferred← citeshttps://doi.org/10.1007/s00508-021-01922-yopenalex-snapshot
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2
inferred← citeshttps://doi.org/10.1007/s11908-021-00752-3openalex-snapshot
Status Report on COVID-19 Vaccines Development
inferred← citeshttps://doi.org/10.1007/s12010-022-04181-3openalex-snapshot
SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders
inferred← citeshttps://doi.org/10.1016/b978-0-323-90248-9.00014-0openalex-snapshot
RNA-based vaccines against SARS-CoV-2
inferred← citeshttps://doi.org/10.1016/j.biologicals.2021.08.001openalex-snapshot
Animal experiments show impact of vaccination on reduction of SARS-CoV-2 virus circulation: A model for vaccine development?
inferred← citeshttps://doi.org/10.1016/j.coviro.2023.101375openalex-snapshot
Pathogenesis of severe acute respiratory syndrome coronavirus-2 in nonhuman primates
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2023.104198openalex-snapshot
Advances, opportunities and challenges in developing therapeutic cancer vaccines
inferred← citeshttps://doi.org/10.1016/j.ebiom.2022.104264openalex-snapshot
Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach
inferred← citeshttps://doi.org/10.1016/j.intimp.2021.107679openalex-snapshot
Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms
inferred← citeshttps://doi.org/10.1016/j.jconrel.2021.03.043openalex-snapshot
The dawn of mRNA vaccines: The COVID-19 case
inferred← citeshttps://doi.org/10.1016/j.molmed.2021.12.001openalex-snapshot
Medical imaging of pulmonary disease in SARS-CoV-2-exposed non-human primates
inferred← citeshttps://doi.org/10.1016/j.omtm.2022.10.001openalex-snapshot
A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses
inferred← citeshttps://doi.org/10.1016/j.vaccine.2021.06.057openalex-snapshot
One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model
inferred← citeshttps://doi.org/10.1016/s1473-3099(21)00677-0openalex-snapshot
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
inferred← citeshttps://doi.org/10.1021/acs.nanolett.1c01284openalex-snapshot
Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection
inferred← citeshttps://doi.org/10.1038/s41392-022-00950-yopenalex-snapshot
Advances in COVID-19 mRNA vaccine development
inferred← citeshttps://doi.org/10.1038/s41467-021-24339-7openalex-snapshot
CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
inferred← citeshttps://doi.org/10.1038/s41467-022-31005-zopenalex-snapshot
Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection
inferred← citeshttps://doi.org/10.1038/s41541-025-01103-2openalex-snapshot
A systems biology approach to define SARS-CoV-2 correlates of protection
inferred← citeshttps://doi.org/10.1038/s41586-021-03275-yopenalex-snapshot
BNT162b vaccines protect rhesus macaques from SARS-CoV-2
inferred← citeshttps://doi.org/10.1088/1748-605x/acecebopenalex-snapshot
Future prospects in mRNA vaccine development
inferred← citeshttps://doi.org/10.1093/infdis/jiae056openalex-snapshot
A Bivalent Adenovirus-Vectored Vaccine Induces a Robust Humoral Response, but Does Not Protect Cynomolgus Macaques Against a Lethal Challenge With Sudan Virus
inferred← citeshttps://doi.org/10.1101/2021.05.13.443734openalex-snapshot
Optimised non-coding regions of mRNA SARS-CoV-2 vaccine CV2CoV improves homogeneous and heterogenous neutralising antibody responses
inferred← citeshttps://doi.org/10.1101/2021.08.13.456316openalex-snapshot
Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman Primates
inferred← citeshttps://doi.org/10.1101/2021.11.08.467773openalex-snapshot
A self-amplifying mRNA COVID-19 vaccine drives potent and broad immune responses at low doses that protects non-human primates against SARS-CoV-2
inferred← citeshttps://doi.org/10.1126/sciadv.aei4853openalex-snapshot
Exposure route, not dose, is the primary driver of infection patterns for a respiratory virus
inferred← citeshttps://doi.org/10.1146/annurev-med-042420-112725openalex-snapshot
mRNA Vaccines in the COVID-19 Pandemic and Beyond
inferred← citeshttps://doi.org/10.12688/openreseurope.14375.1openalex-snapshot
Assessment of the efficacy of SARS-CoV-2 vaccines in non-human primate studies: a systematic review
inferred← citeshttps://doi.org/10.20344/amp.16096openalex-snapshot
Hypersensitivity Reactions to Vaccines: Current Evidence and Standards for SARS-CoV-2 Vaccines
inferred← citeshttps://doi.org/10.31219/osf.io/u3fwjopenalex-snapshot
Assessment of the efficacy of SARS-CoV-2 vaccines in non-human primate studies - a systematic review
inferred← citeshttps://doi.org/10.3389/fimmu.2021.680134openalex-snapshot
Neutrophils and COVID-19: Active Participants and Rational Therapeutic Targets
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1166664openalex-snapshot
Pre-clinical models to define correlates of protection for SARS-CoV-2
inferred← citeshttps://doi.org/10.3389/fmicb.2022.984536openalex-snapshot
Viral vector and nucleic acid vaccines against COVID-19: A narrative review
inferred← citeshttps://doi.org/10.3390/v13081645openalex-snapshot
Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates
inferred← citeshttps://doi.org/10.3390/vaccines10081209openalex-snapshot
Recent Updates on mRNA Vaccines
inferred← citeshttps://doi.org/10.3390/vaccines10081251openalex-snapshot
Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses
inferred← citeshttps://doi.org/10.3390/vaccines9010061openalex-snapshot
Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans
inferred← citeshttps://doi.org/10.3390/vaccines9020147openalex-snapshot
SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond
inferred← citeshttps://doi.org/10.3390/vaccines9080886openalex-snapshot
COVID-19 Research: Lessons from Non-Human Primate Models
inferred← citeshttps://doi.org/10.3390/vaccines9111345openalex-snapshot
The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview
inferred← citeshttps://doi.org/10.36105/psrua.2021v1n2.03openalex-snapshot
mRNA-based COVID-19 vaccines: a new age
inferred← citeshttps://doi.org/10.46683/jmvi.2020.20openalex-snapshot
mRNA Based SARS-CoV-2 Vaccines and Ongoing Researches
inferred← citeshttps://doi.org/10.64898/2026.03.03.709384openalex-snapshot
Exposure route drives SARS-CoV-2 infection patterns in non-human primates
inferred← citeshttps://doi.org/10.7150/ijbs.59233openalex-snapshot
mRNA vaccines for COVID-19: what, why and how
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.